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Peoples of the Arctic and sub-Arctic regions live in 
social and physical environments that differ substantially 
from those of their more southern-dwelling counterparts. 
The cold northern climate keeps people indoors, amplify-
ing the effects of household crowding, smoking, and inad-
equate ventilation on person-to-person spread of infectious 
disease. The emergence of antimicrobial drug resistance 
among bacterial pathogens, the reemergence of tubercu-
losis, the entrance of HIV into Arctic communities, and the 
specter of pandemic inﬂ  uenza or the sudden emergence 
and introduction of new viral pathogens such as severe 
acute respiratory syndrome are of increasing concern to 
residents, governments, and public health authorities. The 
International Circumpolar Surveillance system is a network 
of hospital, public health agencies, and reference labora-
tories throughout the Arctic linked together to collect, com-
pare, and share uniform laboratory and epidemiologic data 
on infectious diseases and assist in the formulation of pre-
vention and control strategies.
A
rctic populations have historically endured the debili-
tating effects of both endemic and epidemic infectious 
diseases (1,2). The introduction of antimicrobial drugs 
and vaccines and the establishment of robust public health 
systems have greatly reduced illness and deaths caused 
by infectious diseases in many Arctic countries. Despite 
these interventions, high rates of invasive diseases caused 
by bacterial pathogens such as Streptococcus pneumoniae 
(3–5),  Haemophilus inﬂ  uenzae ( 6),  Helicobacter pylori 
(7,8), and Mycobacterium tuberculosis (9–12) continue to 
persist. In addition, the emergence of antimicrobial drug 
resistance among bacterial pathogens once easily treated 
with commonly used antibiotics (10,13–15), the entrance 
of HIV into Arctic communities (10,16), and the specter of 
pandemic inﬂ  uenza or the sudden emergence and introduc-
tion of new viral pathogens such as severe acute respiratory 
syndrome (SARS) are of increasing concern to residents, 
governments, and public health authorities of all Arctic 
countries.
Social and Physical Environment
Peoples of the Arctic and sub-Arctic regions live in 
social and physical environments that differ substantially 
from those of their more southern-dwelling counterparts 
(17). The circumpolar region can be deﬁ  ned as a region 
that extends north of 60° north latitude, borders the Arctic 
Ocean, and includes all or northern parts of 8 nations: the 
United States (Alaska), Canada, Greenland, Iceland, Nor-
way, Finland, Sweden, and the Russian Federation (Figure 
1). Climate in the Arctic varies geographically from severe 
cold in arid uninhabited regions to temperate forests bor-
dering coastal agrarian regions. 
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Approximately 4 million people live in the Arctic; al-
most half reside in northern regions of the Russian Federa-
tion. The populations of these countries comprise varying 
proportions of European and indigenous ancestry. The Arc-
tic is the homeland of the Eskimo; the Inuit of Greenland, 
northern Canada, and northern Alaska; the Yupik of west-
ern Alaska and eastern coastal regions of the Russian Far 
East; and the Aleut of the Aleutian Chain. The interior and 
western coastal regions of northern Canada and Alaska are 
the homes of a wide variety of North American Indian, lin-
guistically distinct groups, including the Athabaskan, Eyak, 
Tlingit, Gwich’in, and Metis. In Alaska the collective termi-
nology for persons of indigenous ancestry is Alaska Native. 
Although the group is not registered in ofﬁ  cial statistics, 
the Saami people inhabit circumpolar regions of Norway, 
Finland, and Sweden. The Russian census recognizes (from 
West to East) the Saami, Nenets, Khanty, Sel’kup, Enets, 
Nganasan, Dolgan, Even, Chukchi, Chuvan, and Eskimo/
Inuit-Yupik of the Russian Far East. Arctic populations 
have certain demographic characteristics that separate them 
from populations in more southern regions. Birth and mor-
tality rates are higher, and life expectancy is lower; a high 
proportion of the population is thus of younger age (1). In 
remote regions of the North American Arctic, Greenland, 
and the northern Russian Federation, many residents live 
in small, isolated communities that are dependent on hunt-
ing and ﬁ  shing with little or no economic infrastructure. In 
these remote regions, public health and acute-care systems 
are often marginal, sometimes poorly supported, and in 
some cases nonexistent. 
The Arctic is well known as a vast source of natural 
resources such as ﬁ  sh, forests, oil, gas, and metal ores. 
Exploitation of these resources requires both infrastruc-
ture development and improved transportation. However, 
communities once isolated are now linked by air to larg-
er urban centers, which provides daily access not only to 
secondary and tertiary healthcare, but also to national and 
international transportation, tourism, and trade. In Iceland, 
northern Norway, Finland, Sweden, and the more densely 
populated regions of the North American Arctic, Green-
land, and the northern Russia Federation, a more afﬂ  uent 
economic mixture has emerged because of light industry; 
oil, gas, and mineral development; transportation and agri-
culture; and more sophisticated systems of healthcare and 
public health. 
Inadequate Housing/Crowded Living Conditions 
In smaller isolated communities, inadequate housing is 
an important determinant of infectious diseases. The cold 
northern climate keeps persons indoors, which ampliﬁ  es 
the effects of household crowding, smoking, and inade-
quate ventilation. Crowded living conditions increase per-
son-to-person spread of infectious diseases and favor the 
transmission of respiratory diseases (18–20), tuberculosis 
(12), gastrointestinal diseases (21), and skin infections (22). 
In many smaller isolated communities, inadequate sewage 
disposal systems and water supplies pose a substantial risk 
to health, resulting in periodic epidemics of diseases trans-
mitted by the fecal-oral route (21,23).
Overuse of Antimicrobial Drugs
Empiric use, and possible overuse, of antimicrobi-
al agents in remote Arctic regions has contributed to the 
emergence of bacterial strains now resistant to commonly 
used antibiotics. In the northern regions of the Russian 
Federation, underfunding of tuberculosis treatment pro-
grams have resulted in an unpredictable supply of antibi-
otics, which contributes to poor adherence and emergence 
of multidrug-resistant tuberculosis (10). In remote Alaskan 
villages, lack of ready access to laboratory conﬁ  rmation of 
bacterial pathogens may contribute to overuse of antimi-
crobial agents. In addition, the presence of antimicrobial 
drug–resistant bacterial clones has led to an increase in 
infections with multidrug-resistant S. pneumoniae (24,25), 
methicillin-resistant Staphylococcus aureus (13), and clar-
thromycin- and metronidazole-resistant H. pylori (14).
Role of Surveillance
As in other parts of the world, a key component of 
prevention and control of infectious diseases in Arctic re-
gions is surveillance. Effective surveillance can facilitate 
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Figure 1. The circumpolar region and nonindigenous and indigenous 
populations of the Arctic. (Adapted from [17].) INTERNATIONAL POLAR YEAR  PERSPECTIVE
timely control of outbreaks, inform public health ofﬁ  cials’ 
decisions on resource allocation, and provide data to adjust 
prevention and control strategies to maximize their effects. 
For example, population-based surveillance for invasive 
H. inﬂ  uenzae type b (Hib) disease in the US Arctic dem-
onstrated prevaccine incidence rates of invasive disease of 
601 cases and 129 cases per 100,000/population in Alaska 
Native and non-Native children <5 years of age, respective-
ly (26). Immunization programs that use the Hib conjugate 
vaccine were implemented in the US Arctic in 1991 and 
resulted in a >10-fold decline in Hib cases in Alaska Native 
children. However, in May of 1996, continued surveillance 
detected 4 cases of invasive Hib in children <2 years, and 
during the next 12 months 10 cases occurred. Most cases 
were in infants who received 1–2 doses of Hib vaccine af-
ter a statewide change in 1996 to a vaccine that was less 
immunogenic after the ﬁ  rst dose (27,28). This experience 
demonstrated the need for continued surveillance after the 
implementation of a successful vaccine program and the 
shortcomings of generalizing data from other countries or 
regions to develop public health policy in the Arctic.
Similarly, surveillance for invasive disease caused 
by S. pneumoniae, established in the US Arctic in 1986, 
showed that Alaska Natives had the highest reported aver-
age overall rate for invasive pneumococcal disease in the 
world (62 cases/100,000 population), which was 4× higher 
than the rate for non-Natives (16 cases/100,000) (5). Among 
Alaska Native children <2, the rate was 450 cases/100,000 
versus 129 cases/100,000 among non-Native children. This 
surveillance system ﬁ   rst detected decreased susceptibil-
ity to penicillin in the mid-1980s. Although these isolates 
were only moderately resistant to penicillin, resistance to 
multiple antimicrobial drugs was also found by 1989. Iso-
lates fully resistant to penicillin detected in 1993 were ﬁ  rst 
recovered from patients living in urban points of entry to 
the US Arctic and were indistinguishable from multidrug-
resistant strains circumnavigating the globe (24,25). In the 
US Arctic, the proportion of pneumococcal isolates fully 
resistant to penicillin increased from 0% in 1991 to 6.1% 
in 1998, and the proportion of isolates that were resistant 
to >2 classes of antimicrobial agents increased from 4.7% 
in 1991 to 17.7% in 1998. In the US Arctic, the 23-valent 
pneumococcal polysaccharide vaccine is recommended 
for all persons >55 years of age; however, this vaccine re-
mains underused. In 2001, the heptavalent pneumococcal 
conjugate vaccine (PCV7) was introduced to the childhood 
vaccination schedule, and by 2003, vaccine-type invasive 
pneumococcal disease rates had declined by 91% among 
Alaska Native children <2 years of age and by 80% among 
non-Native children <2 years of age. A 40% reduction of 
invasive pneumococcal disease in adults of all ethnicities 
suggests an indirect impact or herd effect of this vaccine in 
nonvaccinated persons. In addition, the use of PCV7 in this 
population has reduced the proportion of invasive disease 
caused by isolates resistant to penicillin, erythromycin, and 
cotrimoxazole (29).
These examples demonstrate the feasibility of conduct-
ing population-based surveillance to monitor the effects of 
implemented vaccination programs in reducing the extent 
of invasive disease caused by 2 common bacterial patho-
gens in an Arctic region. Population-based surveillance of 
diseases of concern, including invasive bacterial diseases, 
is conducted by public health agencies in Canada, Green-
land, Iceland, Norway, Finland, and Sweden. Linkage of 
these surveillance systems would create the beginnings of 
a circumpolar network of hospitals, public health agencies, 
and reference laboratories throughout the Arctic to collect, 
compare, and share uniform laboratory and epidemiologic 
data on infectious diseases of concern, and assist in the for-
mulation of prevention and control strategies.
International Circumpolar Surveillance
In 1998, the Arctic Investigations Program (AIP) of the 
Centers for Disease Control and Prevention, together with 
Health Canada’s Bureau of Infectious Disease Laboratories 
Centres for Disease Control, now the Public Health Agency 
of Canada’s Center for Infectious Disease Prevention and 
Control, proposed the establishment of an International 
Circumpolar Surveillance (ICS) system for the detection of 
infectious diseases of concern in the Arctic (30). The initial 
priority for ICS was the invasive bacterial diseases caused 
S. pneumoniae, H. inﬂ  uenzae, Neisseria meningitidis, and 
groups A and B streptococci.
ICS capitalizes on existing national infectious disease 
surveillance systems and existing long-standing circum-
polar collaborative relationships forged through the Arc-
tic Council (www.arctic-council.org) and the International 
Union for Circumpolar Health (www.iuch.org). The Arctic 
Council is a ministerial forum promoting cooperation and 
coordination between Arctic nations on common Arctic 
concerns and provides a unique opportunity to partner with 
Arctic nation ministries of health, nongovernmental orga-
nizations, and indigenous peoples’ organizations to address 
health concerns of circumpolar communities. The Interna-
tional Union for Circumpolar Health is a nongovernmental 
organization comprising the memberships of 5 circumpolar 
health organizations that promote circumpolar cooperation 
on Arctic human health.
In 1999, a pilot surveillance system was established to 
monitor reported cases of invasive pneumococcal disease 
from 23 clinical laboratories in Alaska and 14 clinical labo-
ratories in the northern Canadian Arctic above 60° north 
latitude, including the Yukon and Northwest Territories, 
Nunavut, northern Quebec, and Labrador (Figure 2).
Pneumococcal isolates from patients identiﬁ  ed with 
invasive disease were forwarded to reference laborato-
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ries in the US Arctic (AIP) and northern Canada at the 
National Center for Streptococcus (NCS), Edmonton, Al-
berta, or Laboratoire de Sante Publique, Quebec (LSPQ), 
respectively. Identiﬁ  ed cases were also reported to local 
public health personnel, who reviewed and provided clini-
cal, demographic, and vaccination history. Case and cul-
ture information was forwarded to the ICS coordinator at 
AIP for analysis, report generation, and dissemination. In 
2000, Greenland joined ICS. Pneumococcal isolates from 
patients with invasive disease were forwarded from 15 dis-
trict hospitals ﬁ  rst to the Dronning Ingrids Hospital labo-
ratory in Nuuk, Greenland, and then to the Staten Serum 
Institut (SSI), Copenhagen, Denmark, for serotyping and 
susceptibility testing. Iceland, Norway, and Finland joined 
ICS in 2001, reporting national pneumococcal disease sur-
veillance and laboratory information to ICS annually.
Surveillance of other invasive bacterial diseases (H. 
inﬂ  uenzae, N. meningitidis, groups A and B streptococci) in 
the US Arctic, northern Canada, and Greenland was added 
to ICS in 2000. The northern region of Sweden, Norrbotten, 
joined ICS in 2003, reporting invasive diseases caused by 
S. pneumoniae, H. inﬂ  uenzae, N. meningitidis, and groups 
A and B streptococci.
An ICS quality control exchange program was institut-
ed in 1999 among the 3 reference laboratories (AIP, NCS, 
LSPQ) for serotyping and antimicrobial susceptibility test-
ing of S. pneumoniae (31). The program was extended to 
SSI in 2004. In 2005, an ICS quality control exchange pro-
gram for serotyping of isolates of H. inﬂ  uenzae and N. men-
ingitidis was implemented by the National Microbiology 
Laboratory, Public Health Agency of Canada, in Winnipeg, 
Manitoba.
The priorities and overall direction of ICS are gov-
erned by a steering committee consisting of 2 representa-
tives from each participating country; representation from 
World Health Organization European regional ofﬁ  ce, Co-
penhagen; the Indigenous Peoples Secretariat; and Russian 
Association of Indigenous Peoples of the North. Other in-
fectious diseases of concern identiﬁ  ed by the steering com-
mittee , and therefore eligible for circumpolar surveillance, 
include hepatitis B, tuberculosis, HIV/AIDS, and acute re-
spiratory virus diseases such as respiratory syncytial virus 
infections in infants. Surveillance of invasive bacterial dis-
eases is coordinated by a subcommittee, the Invasive Bac-
terial Disease Working Group. As anticipated surveillance 
for other ICS priority diseases is implemented, similar co-
ordinating working groups led by other partner countries 
will be established.
Almost half of the circumpolar region consists of 
northern regions of the Russian Federation, which to its 
west borders the Arctic regions of Norway and Finland, 
and to its east is within 2 miles of the US Arctic. The Rus-
sian Federation’s communicable disease control systems 
evolved separately from western public health systems and 
consist of relatively large federal, regional, disease-specif-
ic, sector-speciﬁ  c (prisons, military), and largely clinical 
case-based reporting systems (10). These differences, to-
gether with the relative isolation of northern and far-eastern 
regions of the Russian Federation, the language barrier, and 
absence of information exchange, have led to some difﬁ  -
culties in establishing cross-border cooperation in infec-
tious disease prevention and control. However, because of 
a sharp rise in the 1990s in the incidence of communicable 
diseases such as HIV, sexually transmitted diseases, and 
tuberculosis (including multidrug-resistant tuberculosis) in 
the Baltic and Barents Sea regions, several initiatives are 
now aimed at improving cooperation in infectious disease 
prevention and control between countries of northwestern 
Europe and adjacent regions of the Russian Federation. For 
example, in 1999 the Norwegian Institute of Public Health, 
together with other Nordic state epidemiologists, estab-
lished a program to strengthen infectious disease control in 
the Barents and Baltic Sea states and has since established a 
framework for communicable disease surveillance commu-
nication and training in northern Europe (www.epinorth.
org). These activities provide a model for expanding coop-
eration and developing partnerships for the exchange of in-
fectious disease surveillance information in other northern 
and far-eastern regions of the Russian Federation.
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Figure 2. The International Circumpolar Surveillance system 
participating regions (dark gray), laboratories (small dots), and 
reference laboratories (large dots).INTERNATIONAL POLAR YEAR  PERSPECTIVE
Impact of ICS
The ability of ICS to collect and share standardized, 
uniform laboratory and epidemiologic data on infectious 
diseases of concern in Arctic countries has already proved 
valuable in the formulation of prevention and control strat-
egies in regions with small but at-risk Arctic populations. 
In 2000, ICS data were used to identify an outbreak of 
S. pneumoniae serotype 1 invasive disease that occurred 
among young adults in 2 northern regions of Canada 
(32,33). This investigation, together with data from Alaska 
that indicated that 78%–84% of invasive pneumococcal 
disease among children <2 years of age could be prevented 
by using PCV7, resulted in the implementation of vaccine 
programs in 3 northern regions of Canada using both the 
23-valent polysaccharide vaccine and PCV7 in 2002. The 
introduction of PCV7 in the US Arctic (2001) and north-
ern Canada (2002) has resulted in a rapid decrease in the 
proportion of isolates resistant to penicillin and other anti-
microbial drugs, compared with the situation in countries 
not using the vaccine (Iceland and Finland) (34). Continued 
surveillance of invasive pneumococcal disease by ICS in 
these regions will monitor the impact and effectiveness of 
vaccine programs for preventing invasive pneumococcal 
disease and antimicrobial drug–resistant infections in these 
high-risk populations (34).
The reemergence of invasive disease caused by Hib in 
the US Arctic in 1996 following a change in conjugate vac-
cine type emphasized the need for continued surveillance 
to monitor vaccine impact, as well as to detect the poten-
tial emergence of disease caused by nonvaccine serotypes. 
Non–Hib (serotypes a, c, d, e, f) is uncommon as a cause of 
invasive disease in children; however, with the decline in 
Hib disease, the importance of infections caused by other 
nonvaccine serotypes has increased. In a 6-month period of 
2003, 5 cases of H. inﬂ  uenzae type a (Hia) were detected in 
3 infants in 1 remote region of the US Arctic (35). Between 
2000 and 2004, 72 cases of serotype-conﬁ  rmed H. inﬂ  uen-
zae infection were detected by ICS in Alaska and Canada 
(36). Of these, 34 (47%) were Hia, and 22 (65%) occurred 
in aboriginal people with a median age of 1.1 years. Hia is 
now the most common H. inﬂ  uenzae serotype seen in the 
North American Arctic, with the highest rates among in-
digenous children. Further research is needed to determine 
sequelae, risk factors, outbreak potential, and the utility of 
chemoprophylaxis for this disease.
Arctic Change and Infectious 
Diseases Surveillance
A common concern among peoples of the Arctic is the 
rapid pace of economic change and modernization occur-
ring in many communities, which will bring new challeng-
es to the health and well-being of Arctic residents (19,37). 
The increasing national and international travel by Arctic 
residents and increasing access to remote communities by 
national and international seasonal workforce and tourists 
have greatly increased the risk of importing infectious dis-
eases to remote communities.
Climate change is also predicted to have major effects 
within the Arctic (38). The average Arctic temperature has 
risen at almost twice the rate of that in the rest of the world 
in the last 2 decades and could cause changes in the in-
cidence and geographic distribution of infectious diseases 
already present in Arctic regions (39). For example, an 
outbreak of Vibrio parahemolyticus–related gastroenteritis 
was reported in July 2004 among cruise ship passengers 
that consumed raw, farmed oysters in the Prince William 
Sound area of Alaska (≈60° north latitude), >1,000 km 
further north than previous reported outbreaks. The July-
August water temperature of the oyster farm had increased 
0.21°C per year since 1997; 2004 was the ﬁ  rst summer on 
record that the mean water temperature exceeded 15°C, the 
threshold temperature for the harvest of implicated oysters, 
which suggests that the ocean warming trend was respon-
sible for this outbreak (40). Similarly, higher ambient tem-
peratures in the Arctic may result in an increase in other 
temperature-sensitive foodborne diseases and inﬂ  uence the 
incidence of zoonotic infectious diseases by changing the 
populations and range of animal hosts and insect vectors. 
The melting of the permafrost together with an increase 
in extreme weather events such as ﬂ  ooding may result in 
damage to water and waste disposal systems, which may in 
turn increase community outbreaks of foodborne and wa-
ter-borne infections. Temperature and humidity markedly 
inﬂ  uence the distribution, density, and biting behavior of 
many arthropod vectors, which again may inﬂ  uence the in-
cidence and northern range of many vector-borne diseases 
(39). These examples emphasize the need for an estab-
lished surveillance network in Arctic regions for monitor-
ing emerging climate-sensitive infectious diseases.
Future Directions
ICS provides a model for international surveillance of 
infectious diseases and collaboration between clinical hos-
pital and public health references laboratories and public 
health centers and institutes. The system currently provides 
standardized laboratory and epidemiologic data on invasive 
bacterial diseases that are comparable across borders and 
can be used to evaluate intervention strategies. However, 
the system also provides an infrastructure that can be used 
to monitor and respond to other emerging infectious dis-
ease threats. Tuberculosis presents a continuing challenge 
to the public health communities of the US Arctic, northern 
Canada, Greenland, and the Russian Federation. The estab-
lishment of an ICS tuberculosis working group would en-
hance ongoing efforts to reduce the rates of disease in these 
regions by sharing knowledge, methods, and surveillance 
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data. Because more than half of the circumpolar region is 
contained within the Russian Federation, efforts should be 
made to engage and develop partnerships with public health 
authorities in these regions to learn more about infectious 
diseases of concern, systems of surveillance, and interests 
in sharing infectious disease surveillance information.
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